"Myeloblastin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polymorphonuclear leukocyte-derived serine protease that degrades proteins such as ELASTIN; FIBRONECTIN; LAMININ; VITRONECTIN; and COLLAGEN. It is named for its ability to control myeloid cell growth and differentiation.
| Descriptor ID |
D053146
|
| MeSH Number(s) |
D08.811.277.656.300.760.530 D08.811.277.656.959.350.530
|
| Concept/Terms |
Myeloblastin- Myeloblastin
- Leukocyte Proteinase 3
- Proteinase 3, Leukocyte
- Myeloblastin, Human
- Human Myeloblastin
- N-Proteinase 4
- N Proteinase 4
- PRTN3 Gene Protein
- Protein, PRTN3 Gene
- Neutrophil Proteinase 3, Human
- Neutrophil Proteinase 4
- Proteinase 4, Neutrophil
- Proteinase 3
- Wegener Autoantigen
- Autoantigen, Wegener
- C-ANCA Antigen
- Antigen, C-ANCA
- C ANCA Antigen
- Azurophil Granule Protein 7
- Neutrophil Proteinase 3
- Proteinase 3, Neutrophil
|
Below are MeSH descriptors whose meaning is more general than "Myeloblastin".
Below are MeSH descriptors whose meaning is more specific than "Myeloblastin".
This graph shows the total number of publications written about "Myeloblastin" by people in this website by year, and whether "Myeloblastin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloblastin" by people in Profiles.
-
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021 Jul-Aug; 18(4):14791641211032547.
-
Proteinase-3, a serine protease which mediates doxorubicin-induced apoptosis in the HL-60 leukemia cell line, is downregulated in its doxorubicin-resistant variant. Oncogene. 2002 Aug 01; 21(33):5160-74.